Not exact matches
Fully implemented targeted sequencing -
based assays in routine
diagnostic pathology laboratories are currently lacking in lymphoid cancer care,» explained Christian Steidl, MD, Senior Scientist at the BC Cancer and Associate Professor in the Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
So we wanted to elucidate the molecular
basis of that resistance in the population and design a field applicable
diagnostic assay for its monitoring.»
SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular
diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer
Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population -
based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.
The LymphoTrack ® Dx TRB
Assay for the Illumina MiSeq ® is an in vitro
diagnostic product intended for next - generation sequencing (NGS)
based determination of the frequency distribution of TRB gene rearrangements in patients suspected with having lymphoproliferative disease.
Esko is collaborating with Zacharon Pharmaceuticals, a San Diego -
based biotechnology company, to develop a commercial
diagnostic assay for differentiating forms of MPS from urine and blood samples, a screening test for newborns and a tool for measuring the biochemical response of MPS patients to existing and novel therapies.
It is a paper
based vertical flow microarray
assay that could find use in future point of care affinity proteomic applications, for instance in the fields of autoimmunity, allergy, infection or cancer
diagnostics.